- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1950
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Moxetumomab Pasudotox: First Global Approval ; volume:79 ; number:1 ; day:5 ; month:1 ; year:2019 ; pages:105 ; date:1.2019
Drugs ; 79, Heft 1 (5.1.2019), 105, 1.2019
- Creator
-
Dhillon, Sohita
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-018-1049-5
- URN
-
urn:nbn:de:101:1-2019022023284746779583
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dhillon, Sohita
- SpringerLink (Online service)
Other Objects (12)
Correction to: Elagolix: First Global Approval
Correction to: Ivosidenib: First Global Approval
Correction to: Sarecycline: First Global Approval
Correction to: Fremanezumab: First Global Approval
Correction to: Delafloxacin: First Global Approval
Correction to: Revefenacin: First Global Approval
Correction to: Caplacizumab: First Global Approval
Correction to: Ibalizumab: First Global Approval
Correction to: Polatuzumab Vedotin: First Global Approval
Correction to: Andexanet Alfa: First Global Approval
Correction to: Lonafarnib: First Approval
Correction to: Pexidartinib: First Approval
Correction to: Elagolix: First Global Approval
Correction to: Ivosidenib: First Global Approval
Correction to: Sarecycline: First Global Approval
Correction to: Fremanezumab: First Global Approval
Correction to: Delafloxacin: First Global Approval
Correction to: Revefenacin: First Global Approval
Correction to: Caplacizumab: First Global Approval
Correction to: Ibalizumab: First Global Approval
Correction to: Polatuzumab Vedotin: First Global Approval
Correction to: Andexanet Alfa: First Global Approval
Correction to: Lonafarnib: First Approval
Correction to: Pexidartinib: First Approval
Correction to: Elagolix: First Global Approval
Correction to: Ivosidenib: First Global Approval
Correction to: Sarecycline: First Global Approval
Correction to: Fremanezumab: First Global Approval
Correction to: Delafloxacin: First Global Approval
Correction to: Revefenacin: First Global Approval
Correction to: Caplacizumab: First Global Approval
Correction to: Ibalizumab: First Global Approval
Correction to: Polatuzumab Vedotin: First Global Approval
Correction to: Andexanet Alfa: First Global Approval
Correction to: Lonafarnib: First Approval